4-氨基-5-溴-2-氯嘧啶 | 205672-25-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氨基-5-溴-2-氯嘧啶
• 中文别名: 2-氯-5-溴-4-氨基嘧啶；2-氯-4-氨基-5-溴嘧啶；4-氯-2-(三氟甲基)苯基硼酸
• 英文名称: 5-bromo-2-chloropyrimidin-4-amine
• 英文别名: 4-amino-5-bromo-2-chloropyrimidine
• CAS: 205672-25-9
• 化学式: C₄H₃BrClN₃
• 分子量: 208.445
• InChiKey: QOWALNIZDHZTSM-UHFFFAOYSA-N

物化性质

• 熔点：
  187-188 °C(Solv: acetonitrile (75-05-8))
• 沸点：
  369.8±22.0 °C(Predicted)
• 密度：
  1.960±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39,S39
• 危险类别码：
  R22,R37/38,R41,R36/37/38
• 海关编码：
  2933599090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
5-Bromo-2-chloropyrimidin-4-amine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
5-Bromo-2-chloropyrimidin-4-amine
Ingredient name:
CAS number: 205672-25-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C4H3BrClN3
Molecular weight: 208.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (5-Bromo-2-chloropyrimidin-4-amine)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

4-氨基-5-溴-2-氯嘧啶是一种嘧啶类衍生物，用作合成中间体。

制备

在1000毫升三口烧瓶中加入5-溴-2,4-二氯嘧啶和氨水，搅拌并回流反应3～5小时。通过薄层色谱（TLC）追踪反应进程直至完成。将反应液冷却至室温后进行过滤。粗产物依次用200毫升乙醇和500毫升水洗涤，然后干燥。最后，使用三氯甲烷与石油醚体积比为1∶1的混合溶剂重结晶得到白色固体4-氨基-5-溴-2-氯嘧啶。

反应信息

• 作为反应物：
  描述：

  4-氨基-5-溴-2-氯嘧啶 在 四氢呋喃 、 亚硝酸特丁酯 、 二甲基亚砜 作用下， 反应 2.0h， 以27%的产率得到5-溴-2-氯嘧啶
  参考文献：
  名称：

  二甲基亚砜在四氢呋喃中用 t-BuONO 加速芳香胺的还原脱氨基

  摘要：

  已经实现了通过一锅还原脱氨基将芳胺转化为芳烃的有效方法。发现在四氢呋喃中使用 t-BuONO 可以通过二甲基亚砜加速还原脱氨基，并在温和条件下提供具有良好产率的脱氨基产物。讨论了一个合理的机制。

  DOI：

  10.3184/174751918x15402967122774
• 作为产物：
  描述：

  5-溴-2,4-二氯嘧啶 在 氨 作用下， 以 四氢呋喃 为溶剂， 反应 15.0h， 以94%的产率得到4-氨基-5-溴-2-氯嘧啶
  参考文献：
  名称：

  设计和合成7H-吡咯并[2,3-d]嘧啶作为粘着斑激酶抑制剂。第1部分。

  摘要：

  设计并合成了一系列2-氨基-9-芳基-7H-吡咯并[2,3-d]嘧啶，以靶向粘着斑激酶（FAK）。许多这些吡咯并嘧啶对粘着斑激酶表现出低的微摩尔抑制活性，并且它们的初步SAR是通过系统化学修饰而建立的。2-氨基-9-芳基-7H-吡咯并[2,3-d]嘧啶代表了一类新的激酶抑制剂。

  DOI：

  10.1016/j.bmcl.2006.01.053

文献信息

• [EN] BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY<br/>[FR] ACIDES HYDROXAMIQUES BICYCLIQUES UTILES COMME INHIBITEURS DE L'ACTIVITÉ HISTONE DÉSACÉTYLASE CHEZ LE MAMMIFÈRE
  申请人：KANCERA AB

  公开号：WO2017108282A1

  公开（公告）日：2017-06-29

  A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.

  化合物的化学式（Ia）或（Ib）或其药学上可接受的盐。该化合物是组蛋白去乙酰化酶的抑制剂，因此在治疗自身免疫性疾病、精神障碍、神经退行性疾病和过度增生性疾病等方面非常有用。
• New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
  申请人：Laboratorios Almirall, S.A.

  公开号：EP2108641A1

  公开（公告）日：2009-10-14

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。
• [EN] BICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES
  申请人：KALYRA PHARMACEUTICALS INC

  公开号：WO2016183094A1

  公开（公告）日：2016-11-17

  Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

  本文披露了含氮的双环化合物，以及使用本文描述的一个或多个化合物改善和/或治疗本文描述的癌症的药物组合物和方法。
• [EN] PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY<br/>[FR] BIOMARQUEURS PRONOSTIQUES POUR CHIMIOTHÉRAPIE BASÉE SUR UN INHIBITEUR DE TTK
  申请人：NETHERLANDS TRANSLATIONAL RES CENTER B V

  公开号：WO2016166255A1

  公开（公告）日：2016-10-20

  The present invention provides a method for identifying a tumor - in a human individual or in an animal - that is susceptible to treatment with a TTK inhibitor, said method comprising: a] providing a sample of a tumor; b] determining the presence of a mutated CTNNB1 gene in said tumor sample, wherein said mutation is located in exon 3 of CTNNB1 and whereby the presence of a mutated CTNNB1 gene indicates that the tumor is susceptible to treatment with a TTK inhibitor. In an alternative aspect, step b] of the above defined method is replaced by the step of determining the presence of a mutated CTNNB1 protein in said tumor sample, wherein said mutation is located in exon 3 of CTNNB1 and whereby the presence of a mutated CTNNB1 protein indicates that the tumor is susceptible to treatment with a TTK inhibitor. In a further alternative, step b] comprises determining an altered expression of a CTNNB1 regulated gene, whereby an altered expression of a CTNNB1 regulated gene indicates that the tumor is susceptible to treatment with a TTK inhibitor.

  本发明提供了一种用于识别易受TTK抑制剂治疗的人体或动物肿瘤的方法，所述方法包括：a] 提供肿瘤样本；b] 确定肿瘤样本中是否存在突变的CTNNB1基因，其中所述突变位于CTNNB1的第3外显子中，并且存在突变的CTNNB1基因表明肿瘤易受TTK抑制剂治疗。在另一种方面，上述定义方法的步骤b] 被替换为确定肿瘤样本中是否存在突变的CTNNB1蛋白，其中所述突变位于CTNNB1的第3外显子中，并且存在突变的CTNNB1蛋白表明肿瘤易受TTK抑制剂治疗。在进一步的替代方案中，步骤b] 包括确定CTNNB1调控基因的表达改变，其中CTNNB1调控基因的表达改变表明肿瘤易受TTK抑制剂治疗。
• [EN] (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES<br/>[FR] (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOZILINES
  申请人：NETHERLANDS TRANSLATIONAL RES CT B V

  公开号：WO2015155042A1

  公开（公告）日：2015-10-15

  The invention relates to a compound of Formula (I) wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.

  本发明涉及一种公式(I)的化合物，其中R1和R2独立地选自包括可选择性取代的（6-10C）芳基和（1-5C）杂芳基基团在内的组。这些化合物可用于药物组合物中，特别是在癌症治疗中。